Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 10/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.40 |
| ▸ | NPC1 | O15118 | 7/20 | 0.40 |
| ▸ | MAPT | P10636 | 5/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.38 |
| ▸ | GPR3 | P46089 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 3/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.34 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21271494 | 1.00 | RAB9A (0.40) | RAB9ASMN1; SMN2NPC1MAPTALDH1A1 | |
| SCHEMBL28463404 | 0.81 | RAB9A (0.53) | RAB9ASMN1; SMN2NPC1MAPTALDH1A1 | |
| SCHEMBL30238663 | 0.81 | RAB9A (0.53) | RAB9ASMN1; SMN2NPC1MAPTALDH1A1 | |
| SCHEMBL28463403 | 0.81 | RAB9A (0.53) | RAB9ASMN1; SMN2NPC1MAPTALDH1A1 | |
| SCHEMBL20154295 | 0.77 | PDGFRB (0.48) | RAB9ASMN1; SMN2NPC1MAPTALDH1A1 | |
| SCHEMBL21271507 | 0.77 | PDGFRB (0.48) | RAB9ASMN1; SMN2NPC1MAPTALDH1A1 | |
| SCHEMBL21271508 | 0.77 | PDGFRB (0.48) | RAB9ASMN1; SMN2NPC1MAPTALDH1A1 | |
| SCHEMBL29702254 | 0.77 | PDGFRB (0.48) | RAB9ASMN1; SMN2NPC1MAPTALDH1A1 | |
| SCHEMBL28430958 | 0.77 | PDGFRB (0.48) | RAB9ASMN1; SMN2NPC1MAPTALDH1A1 | |
| SCHEMBL20569115 | 0.77 | CYP1A2 (0.39) | RAB9ANPC1GPR3CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111433207-B | As alpha V Pyrrolopyrazine derivatives of integrin inhibitors | 百时美施贵宝公司 | 2023-07-25 | — | — | CN | disclosed |
| CN-110139864-B | Pyrrole amides as alpha V integrin inhibitors | 百时美施贵宝公司 | 2022-08-23 | — | — | CN | disclosed |
| US-11292802-B2 | Substituted tetrahydropyrrolo[1,2-a]pyrazines as alpha v integrin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-04-05 | — | — | US | disclosed |
| US-11292802-B2 | Substituted tetrahydropyrrolo[1,2-a]pyrazines as alpha v integrin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-04-05 | — | — | US | disclosed |
| EP-3707142-B1 | PYRROLOPYRAZINE DERIVATIVES AS ALPHA V INTEGRIN INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-12-08 | — | — | EP | disclosed |
| EP-3707142-B1 | PYRROLOPYRAZINE DERIVATIVES AS ALPHA V INTEGRIN INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-12-08 | — | — | EP | disclosed |
| US-20210163501-A1 | PYRROLOPYRAZINE DERIVATIVES AS ALPHA V INTEGRIN INHIBITORS | BRISTOL MAYERS SQUIBB COMPANY (US) | 2021-06-03 | — | — | US | disclosed |
| US-20210163501-A1 | PYRROLOPYRAZINE DERIVATIVES AS ALPHA V INTEGRIN INHIBITORS | BRISTOL MAYERS SQUIBB COMPANY (US) | 2021-06-03 | — | — | US | disclosed |
| EP-3538528-B1 | PYRROLE AMIDES AS ALPHA V INTEGRIN INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-12-23 | — | — | EP | disclosed |
| EP-3538528-B1 | PYRROLE AMIDES AS ALPHA V INTEGRIN INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-12-23 | — | — | EP | disclosed |
| EP-3707142-A1 | PYRROLOPYRAZINE DERIVATIVES AS ALPHA V INTEGRIN INHIBITORS | Bristol-Myers Squibb Company (US) | 2020-09-16 | — | — | EP | disclosed |
| US-10717736-B2 | Pyrrole amides as alpha V integrin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-07-21 | — | — | US | disclosed |
| US-10717736-B2 | Pyrrole amides as alpha V integrin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-07-21 | — | — | US | disclosed |
| CN-111433207-A | As αVPyrrolopyrazine derivatives of integrin inhibitors | 百时美施贵宝公司 | 2020-07-17 | — | — | CN | disclosed |
| US-20190256512-A1 | PYRROLE AMIDES AS ALPHA V INTEGRIN INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-08-22 | — | — | US | disclosed |
| US-20190256512-A1 | PYRROLE AMIDES AS ALPHA V INTEGRIN INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-08-22 | — | — | US | disclosed |
| WO-2018089360-A1 | PYRROLE AMIDES AS ALPHA V INTEGRIN INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190256512-A1 | PYRROLE AMIDES AS ALPHA V INTEGRIN INHIBITORS | ITGAV, ITGB1, ITGA1 | RAB9A 924/4885SMN1; SMN2 3658/4885NPC1 2916/4885 |
| US-20210163501-A1 | PYRROLOPYRAZINE DERIVATIVES AS ALPHA V INTEGRIN INHIBITORS | ITGB1, ITGAV, ITGB5 | RAB9A 886/4885SMN1; SMN2 3970/4885NPC1 2021/4885 |
| US-11292802-B2 | Substituted tetrahydropyrrolo[1,2-a]pyrazines as alpha v integrin inhibitors | ITGB1, ITGAV, ITGA1 | RAB9A 639/4885SMN1; SMN2 3967/4885NPC1 1979/4885 |
| US-10717736-B2 | Pyrrole amides as alpha V integrin inhibitors | ITGAV, ITGB1, ITGA1 | RAB9A 924/4885SMN1; SMN2 3658/4885NPC1 2916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.